Phase 1 Myositis Clinical Trials
12 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–12 of 12 trials
Recruiting
Phase 1
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting
Phase 1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Phase 1
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled8 locationsNCT06925542
Recruiting
Phase 1Phase 2
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Systemic Lupus ErythematosusDermatomyositisPolymyositis+1 more
Miltenyi Biomedicine GmbH24 enrolled1 locationNCT06347718
Recruiting
Phase 1
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Systemic Sclerosis (SSc)Polyarticular Juvenile Idiopathic ArthritisPrimary Sjogren's Syndrome+1 more
Chongqing Precision Biotech Co., Ltd11 enrolled1 locationNCT07184450
Recruiting
Phase 1
Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Dermatomyositis
Stanford University21 enrolled2 locationsNCT06298019
Recruiting
Phase 1
Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial
Anti-MDA5 Positive Dermatomyositis-Associated RP-ILDRapidly Progressive Interstitial Lung Disease
Li Shiyue10 enrolled1 locationNCT06919380
Recruiting
Phase 1
Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)
DermatomyositisDermatomyositis, Juvenile
Chongqing Precision Biotech Co., Ltd18 enrolled1 locationNCT06686524
Recruiting
Phase 1
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
Juvenile Dermatomyositis
Chongqing Precision Biotech Co., Ltd10 enrolled1 locationNCT06569472
Recruiting
Phase 1
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
DermatomyositisSystemic SclerodermaAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+2 more
Chongqing Precision Biotech Co., Ltd24 enrolled1 locationNCT06056921
Not Yet Recruiting
Phase 1
Pilot study of the treatment of patients with sporadic Inclusion Body Myositis with the Anaplerotic medication Triheptanoin
Sporadic Inclusion body Myositis
Ultragenyx3 enrolled1 locationACTRN12614000082606